Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

Bibliography

• Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009;113(6):6296-303
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115(3):453-74
   PubMed Web of Science ®Google Scholar
• Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007;25(14):1908-15
   PubMed Web of Science ®Google Scholar
• Estey E. New drugs in acute myeloid leukemia. Semin Oncol 2008;35(4):439-48
   PubMed Web of Science ®Google Scholar
• Gore SD. New agents for the treatment of AML recent study findings. Clin Adv Hematol Oncol 2008;6(11):6-8
   PubMedGoogle Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med 2008;358(11):1148-59
   PubMed Web of Science ®Google Scholar
• Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349(21):2042-54
   PubMed Web of Science ®Google Scholar
• Mehnert JM, Kelly WK. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 2007;13(1):23-9
   PubMed Web of Science ®Google Scholar
• Jiang Y, Dunbar A, Gondek LP, Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009;113(6):1315-25
   PubMed Web of Science ®Google Scholar
• Bullinger L, Ehrich M, Dohner K, Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010;115(3):636-42
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002;20(10):2429-40
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10(3):223-32
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106(8):1794-803
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Gattermann N. Valproic acid for the treatment of myeloid malignancies. Cancer 2007;110(5):943-54
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Schmid M, Schlenk R, The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006;106(1):112-19
   PubMed Web of Science ®Google Scholar
• Gojo I, Jiemjit A, Trepel JB, Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007;109(7):2781-90
   PubMed Web of Science ®Google Scholar
• Giles F, Fischer T, Cortes J, A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12(15):4628-35
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science 2001;293(5532):1074-80
   PubMed Web of Science ®Google Scholar
• Linggi BE, Brandt SJ, Sun ZW, Hiebert SW. Translating the histone code into leukemia. J Cell Biochem 2005;96(5):938-50
   PubMed Web of Science ®Google Scholar
• Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009;15(12):3947-57
   PubMed Web of Science ®Google Scholar
• Oki Y, Issa JP. Epigenetic mechanisms in AML – a target for therapy. Cancer Treat Res 2009;145:19-40
   Google Scholar
• Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97(18):10014-19
   PubMed Web of Science ®Google Scholar
• Vrana JA, Decker RH, Johnson CR, Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999;18(50):7016-25
   PubMed Web of Science ®Google Scholar
• Ruefli AA, Ausserlechner MJ, Bernhard D, The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001;98(19):10833-8
   PubMed Web of Science ®Google Scholar
• Takahashi S, Harigae H, Kameoka J, AML1B transcriptional repressor function is impaired by the Flt3-internal tandem duplication. Br J Haematol 2005;130(3):428-36
   PubMed Web of Science ®Google Scholar
• Miller CP, Rudra S, Keating MJ, Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 2009;113(18):4289-99
   PubMed Web of Science ®Google Scholar
• Reikvam H, Ersvaer E, Bruserud O. Heat shock protein 90 – a potential target in the treatment of human acute myelogenous leukemia. Curr Cancer Drug Targets 2009;9(6):761-76
   PubMed Web of Science ®Google Scholar
• Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 2006;108(4):1174-82
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myohanen S, Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21(1):103-7
   PubMed Web of Science ®Google Scholar
• Fiskus W, Rao R, Fernandez P, Molecular and biologic characterization and drug-sensitivity of pan histone deacetylase inhibitor resistant acute myeloid leukemia cells. Blood 2008;112(7):2896-905
   PubMed Web of Science ®Google Scholar
• Park MA, Zhang G, Martin AP, Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther 2008;7(10):1648-62
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Dedes I, Imesch P, Acquired vorinostat resistance shows partial cross-resistance to ‘second-generation’ HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs 2009;20(5):321-33
   PubMed Web of Science ®Google Scholar
• Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res 2007;13(24):7237-42
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Ni X, Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109(1):31-9
   PubMed Web of Science ®Google Scholar
• Richardson P, Mitsiades C, Colson K, Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008;49(3):502-7
   PubMed Web of Science ®Google Scholar
• Richon VM, Emiliani S, Verdin E, A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998;95(6):3003-7
   PubMed Web of Science ®Google Scholar
• Salmi-Smail C, Fabre A, Dequiedt F, Modified CAP group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity. J Med Chem 2010;53(8):3038-47
   PubMed Web of Science ®Google Scholar
• O'Connor OA, Heaney ML, Schwartz L, Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006;24(1):166-73
   PubMed Web of Science ®Google Scholar
• Kelly WK, O'Connor OA, Krug LM, Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23(17):3923-31
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Yang H, Bueso-Ramos C, Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008;111(3):1060-6
   PubMed Web of Science ®Google Scholar
• Rubin EH, Agrawal NG, Friedman EJ, A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 2006;12(23):7039-45
   PubMed Web of Science ®Google Scholar
• Schaefer EW, Loaiza-Bonilla A, Juckett M, A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009;94(10):1375-82
   PubMed Web of Science ®Google Scholar
• Gore SD, Hermes-DeSantis ER. Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches. Cancer Control 2008;15(Suppl):40-9
   PubMedGoogle Scholar
• Miller CP, Ban K, Dujka ME, NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood 2007;110(1):267-77
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Medina EC, Esquivel JA II, Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res 2010;16(1):141-53
   PubMed Web of Science ®Google Scholar
• Urbich C, Rossig L, Kaluza D, HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. Blood 2009;113(22):5669-79
   PubMed Web of Science ®Google Scholar
• Kouraklis G. HDAC inhibitors in leukemia: current status and perspectives. Leuk Res 2009;33(2):207-8
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Tambaro F, Nebiyou Bekele B, Phase II study of vorinostat in combination with idarubicin (Ida) and cytarabine (ara-C) as front line therapy in acute myelogenous leukemia (AML) or higher risk myelodysplastic syndrome (MDS). Blood (ASH Annual Meeting Abstracts) 2009;114(22):1055
   Web of Science ®Google Scholar
• Kadia TM, Yang H, Ferrajoli A, A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 2010;150(1):72-82
   PubMed Web of Science ®Google Scholar
• Gore SD, Baylin S, Sugar E, Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006;66(12):6361-9
   PubMed Web of Science ®Google Scholar
• Raffoux E, delabarthe A, Cras A, Epigenetic Therapy with 5-Azacitidine, Valproic Acid, and ATRA in Patients with High-Risk AML or MDS: results of the French VIVEDEP Phase II Study. Oncotarget 2010;1(5):34-42
   Google Scholar
• Soriano AO, Yang H, Faderl S, Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007;110(7):2302-8
   PubMed Web of Science ®Google Scholar
• Rudek MA, Zhao M, He P, Pharmacokinetics of 5-azacitidine administered with phenyl butyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 2005;23(17):3906-11
   PubMed Web of Science ®Google Scholar
• Silverman LR, Verma A, Odchimar-Reissig R, A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: a New York Cancer Consortium. J Clin Oncol 2008;26(Suppl): Abstract 7000
   Google Scholar
• Kirschbaum M, Gojo I, Goldberg SL, Vorinostat in combination with decitabine for the treatment of relapsed or newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): a phase I, dose-escalation study. Blood (ASH Annual Meeting Abstracts) 2009;114(22):2089
   Web of Science ®Google Scholar
• Bruserud O, Stapnes C, Ersvaer E, Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell. Curr Pharm Biotechnol 2007;8(6):388-400
   PubMed Web of Science ®Google Scholar
• Yaswen P. HDAC inhibitors conquer Polycomb proteins. Cell Cycle 2010;9(14):2705
   PubMed Web of Science ®Google Scholar
• Badros A, Burger AM, Philip S, Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009;15(16):5250-7
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Assouline S, Cortes J, Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 2008;112(4):981-9
   PubMed Web of Science ®Google Scholar
• Byrd JC, Marcucci G, Parthun MR, A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005;105(3):959-67
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Spencer A, Prince HM, Phase IA/II study of oral panobinostat (LBH589), a novel pan-deacetylase inhibitor (DACi) demonstrating efficacy in patients with advanced hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 2008;112(11):958
   Web of Science ®Google Scholar
• Prebet T, Gore SD, Sun Z, Prolonged administration of azacitidine with or without entinostat increases rate of hematologic normalization for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup Trial E1905. Blood (ASH Annual Meeting Abstracts) 2010;116(21);4013
   Web of Science ®Google Scholar
• Garcia-Manero G, Yang AS, Klimek V, Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML). J Clin Oncol 2007;25(18S, June 20 Suppl):7062
   Google Scholar